Summary
This Form 8-K filing by Pfizer Inc. (PFE) on August 15, 2007, primarily announces the submission of XBRL-formatted financial data from its Quarterly Report on Form 10-Q for the period ended July 1, 2007. This submission is part of the SEC's voluntary XBRL pilot program, aimed at testing the eXtensible Business Reporting Language format and its underlying technology. Investors are strongly cautioned that the XBRL data provided in this filing is unaudited and should not be considered a substitute for the official financial statements previously filed with the SEC on August 6, 2007. The purpose of this filing is solely for the technological testing of XBRL. Therefore, this information should not be relied upon for making investment decisions. Investors are directed to the official Form 10-Q filing for accurate and audited financial information pertinent to their investment analysis. The company is complying with SEC regulations regarding the furnishing of this pilot program data, ensuring it does not create liability under Section 18 of the Exchange Act.
Key Highlights
- 1Pfizer Inc. is participating in the SEC's voluntary XBRL pilot program.
- 2The filing includes XBRL-formatted financial data from Pfizer's Q2 2007 10-Q filing.
- 3The XBRL data covers Condensed Consolidated Statements of Income, Balance Sheets, and Cash Flows.
- 4Investors are explicitly warned that the XBRL data is unaudited and unofficial.
- 5This information is for technological testing purposes only and should not be used for investment decisions.
- 6Investors should refer to the official Form 10-Q filed on August 6, 2007, for reliable financial information.